Lymphoma Clinical Trials

A listing of Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 191 clinical trials
Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

The primary objective of the study is to evaluate the efficacy of tislelizumab in participants with relapsed/refractory classical Hodgkin lymphoma, as measured by the overall response rate per

avid
measurable disease
chemotherapy regimen
refractory classical hodgkin lymphoma
cancer
  • 0 views
  • 23 Jun, 2021
  • 23 locations
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare LOXO-305 to other drugs that work in a similar way that have

measurable disease
btk inhibitor
neutrophil count
cancer
ibrutinib
  • 0 views
  • 18 Jun, 2021
  • 64 locations
  • 1270 views
  • 23 Jun, 2021
  • 250 locations
HD21 for Advanced Stages

Primary objective of the trial is to demonstrate non-inferior efficacy of six cycles of BrECADD compared to six cycles of escalated BEACOPP, each followed by radiotherapy to PET-positive residual lesions 2.5 cm, in terms of progression free survival (efficacy objective). If non-inferior efficacy can be shown, the co-primary objective is …

prednisone
cyclophosphamide
vincristine
lymphoma
doxorubicin
  • 0 views
  • 21 Jun, 2021
  • 1 location
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

their epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genes, will be enrolled in this study. The study drug, capmatinib (also known as INC280), is an oral drug that is

epidermal growth factor
systemic therapy
EGFR
measurable disease
epidermal growth factor receptor
  • 0 views
  • 13 Jun, 2021
  • 43 locations
AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer.

This is a modular, multicentre, open-label, non-randomised, Phase I/II, dose-setting and expansion study including an intra-participant ramp-up. AZD4573 will be administered intravenously, in novel combinations with anti-cancer agents, to participants with relapsed/refractory haematological malignancies.

  • 0 views
  • 21 Jun, 2021
  • 25 locations
BI-1808 as a Single Agent and With Pembrolizumab in Treatment of Advanced Malignancies

iRECIST can be applied for efficacy assessment) and subjects with cutaneous T-cell lymphoma (CTCL), specifically Szary Syndrome (SS) and mycosis fungoides (MF). The study will consist of 2 phases

  • 0 views
  • 21 Jun, 2021
  • 8 locations
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

and immune system cancers. Bendamustine is approved to treat other kinds of leukemia and lymphoma, but it has not been used to treat HCL. Pentostatin has been used for more than 20 years to treat HCL

  • 0 views
  • 23 Jun, 2021
  • 1 location
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

This is a Phase 3 study of the PI3K inhibitor Zandelisib (ME-401) in combination with rituximab, in comparison to standard immunochemotherapy (Rituximab-Bendamustine or Rituximab-CHOP) in subjects with relapsed or refractory FL and MZL.

bendamustine
measurable disease
rituximab
cyclophosphamide
chop regimen
  • 0 views
  • 13 Jun, 2021
  • 3 locations
Using T-Cell Alloreactivity and Chimerism to Guide Immunosuppression Minimization in Intestinal Transplantation

The purpose of this study is to investigate the safety and feasibility of giving intestinal transplant patients CD34+ stem cells (the cells that make all the types of blood cells) obtained from their organ donor's bone marrow. The goal of this is to develop a post-transplant treatment strategy that controls …

  • 0 views
  • 21 Jun, 2021